Compare MNKD & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | MFA |
|---|---|---|
| Founded | 1991 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 1.0B |
| IPO Year | 2004 | N/A |
| Metric | MNKD | MFA |
|---|---|---|
| Price | $3.52 | $9.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $8.69 | ★ $11.05 |
| AVG Volume (30 Days) | ★ 6.3M | 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | $10.02 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $8.78 |
| 52 Week High | $6.51 | $10.57 |
| Indicator | MNKD | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 44.02 |
| Support Level | $2.45 | $9.38 |
| Resistance Level | $6.08 | $10.26 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 43.01 | 33.60 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.